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Abstract 
The optimal regimen of antiplatelet therapy for secondary prevention in noncardioembolic ischemic 
stroke remains controversial. We aimed to determine which regimen was associated with the 
greatest reduction in adverse outcomes. We analysed prospectively collected data from the Norfolk 
and Norwich University Hospital Stroke Register (NNUHSR). The sample population consisted of 
3,572 participants (mean age 74.96 ± 12.67) with ischemic stroke, who were consecutively admitted 
between 2003-2015. Patients were placed on one of three antiplatelet regimens at hospital 
discharge; aspirin monotherapy, aspirin plus dipyridamole and clopidogrel. Clopidogrel and aspirin 
plus dipyridamole was compared to aspirin. A direct comparison between clopidogrel and aspirin 
plus dipyridamole was also performed. Outcomes included all-cause mortality and a combined 
endpoint of all-cause mortality and incidence of major adverse cardiac events (stroke or myocardial 
infarction). Cox-regression models adjusted for potential confounders at the following time periods 
after discharge; 0-90 days, 91-365 days and 1-3 years. Aspirin plus dipyridamole was associated 
with a lower risk of mortality at 0-90 days; HR 0.62 (0.43-0.91). Clopidogrel was associated with a 
lower risk of mortality at 1-3 years; HR of 0.39 (0.26-0.60). Similar HRs were observed for the the 
corresponding time points in the composite outcome. In conclusion Patients with non-
cardioembolic stroke may gain maximum benefit from aspirin plus dipyridamole initially (≤1 year) 
with a subsequent switch to clopidogrel, with regard to mortality and MACE outcomes.  
 
Key Words: Ischemic stroke, secondary prevention, antiplatelets, outcomes 
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Introduction 
Antiplatelet agents form the cornerstone of secondary preventative therapy in patients with 
noncardioembolic ischemic stroke. A recent meta-analysis of clinical trials found the combination 
of aspirin plus dipyridamole to be more effective than aspirin monotherapy in reducing the risk of 
stroke and other serious vascular events [1]. The CAPRIE trial found that clopidogrel reduced the 
risk of a combined end-point of ischemic stroke, myocardial infarction or vascular death in patients 
at risk of ischemic events, compared to aspirin. However, this relationship was only statistically 
significant in patients with peripheral vascular disease, not within the ischemic stroke sub-group of 
patients [2]. The PRoFESS trial directly compared clopidogrel with aspirin plus dipyridamole and 
found that both regimens had similar efficacy [3]. National guidelines have made different 
recommendations with regards to the optimal antiplatelet for preventative therapy [4-6]. Due to the 
regarding the optimal antiplatelet therapy for secondary prevention in ischemic stroke, the current 
study aimed to evaluate which antiplatelet therapy had the greatest short and long term efficacy.  
 
Methods 
We retrospectively analysed data from a study population consisting of 3,575 patients with 
ischemic stroke who were admitted consecutively to the Norfolk and Norwich University Hospital 
(NNUH) between January 2003 and May 2015. NNUH is a tertiary regional care centre with a 
catchment population of ~750,000. The methods of data collection used in the NNUH stroke 
register have been reported previously [7]. In brief, data from paper and electronic records were 
prospectively entered into the database by clinical team members. Follow-up mortality status, 
recurrent stroke (ICD10: I63) and myocardial infarction (ICD10-I I21) were ascertained by 
electronic record linkage with the Office of National Statistics. We therefore have almost 100% 
follow up (see Supplementary Figure 1). Only confirmed cases of ischemic stroke, diagnosed using 
a combination of clinical features and imaging (CT or MRI), were included. Ethical approval was 
obtained from the Newcastle and Tyneside National Health Service (NHS) Research Ethics 
Committee (12/NE/0170) and the study protocol was approved by the Steering Committee of the 
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Register. The study therefore conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki. As this was a registry based study, consent was not gained from each individual patient.  
Patients diagnosed with atrial fibrillation (AF) prior to stroke and during the follow-up 
period were excluded in an attempt to remove potential cardioembolic strokes. Furthermore, this 
mitigated the confounding effect of switching from antiplatelet at discharge to anticoagulation at a 
later date (usually 8-12 weeks after ictus). Patients on all other antiplatelet regimens or on any type 
of anticoagulant for other purposes at the time of discharge were also excluded. Patients who died 
as inpatients were not included in order to focus on the relationship between discharge antiplatelet 
and long-term outcomes. Study follow-up therefore begins from the point of hospital discharge with 
discharge antiplatelet therapy as the predictor variable. Patients receiving aspirin and clopidogrel 
both received dosages of 75mg once daily. Patients receiving aspirin + dipyridamole where given a 
combined extended release variant which contained 25mg of aspirin and 200mg of dipyridamole. 
The variables included in the study were age, sex, pre-stroke disability depicted by modified 
Rankin score (0 – 5), Oxfordshire Community Stroke Project (OCSP) classification (Total Anterior 
Circulation Infarction, Partial Anterior Circulation Infarction, Posterior Circulation Infarction, 
Lacunar Infarction), prior antiplatelet use (yes/no) and co-morbidities (Previous Stroke/Transient 
Ischemic Attack, Coronary Heart Disease/Myocardial Infarction, Congestive Heart Failure, 
Hypertension, Hyperlipidemia, Diabetes Mellitus, Peripheral Vascular Disease, Chronic Obstructive 
Pulmonary Disease, Chronic Kidney Disease, Falls, Malignancy, Dementia). The outcomes of 
interest were (1) all-cause mortality and (2) a combined end-point of all-cause mortality and major 
adverse cardiac events defined as either incident stroke or myocardial infarction (mortality & 
MACE). For the latter outcome, the event was censored at the occurrence of whichever occurred 
first out of stroke, myocardial infarction or death. Outcomes were assessed at the following time-
periods; 0 – 90 days, 91 – 365 days and 366 – 1095 days („1 – 3 years‟). These time points were 
chosen in order to assess both short and long term outcomes in a manner that preserved a sufficient 
level of statistical power.  
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The associations between choice of antiplatelet regimen with age, sex, pre-stroke modified 
Rankin score, OCSP Classification, prior-antiplatelet use and co-morbidities were assessed using 
the chi-square test. Cox proportional hazard models were constructed in order to evaluate the 
impact of different antiplatelet therapies on stroke outcomes. Unadjusted and adjusted hazard ratios 
were obtained from univariate and multivariate models. Survival analysis was performed 
controlling for age, sex, pre-stroke modified Rankin score, OCSP classification, prior-antiplatelet 
use, co-morbidities and year of hospital discharge. Statistical analysis was performed using SPSS 
version 24.0 (SPSS Inc., Chicago, Illinois, USA).  
  
Results 
The cohort consisted of 3,575 patients with ischemic stroke. The mean age (SD) was 74.96 
(± 12.67) years and 50.7% were male and the most common stroke subtype was Partial Anterior 
Circulation Stroke (37.3%). Antiplatelet therapy at discharge included 953 (26.7%) patients on 
aspirin, 1,067 (29.8%) on aspirin plus dipyridamole combination and 1,555 (43.5%) on clopidogrel. 
Mean values for person-years of treatment for aspirin monotherapy, aspirin plus dipyridamole and 
clopidogrel were 2.36, 2.51 and 2.66 respectively. During follow-up there were a total of 840 events 
(deaths) for the mortality outcome and 911 events in the composite outcome (732 deaths, 126 
stroke, 53 MI). The apparent discrepancy in mortality frequency between the two outcomes is due 
to the censoring of patients once they experience stroke, MI or mortality in the composite outcome. 
As a result, some patients were censored prior to experiencing mortality, thereby making the 
frequency of mortality appear lower in the combined outcome.   
Table 1 shows sample characteristics by antiplatelet therapy at discharge. Descriptive 
comparison statistics were made using aspirin as the reference point. Aspirin use was associated 
with older age, female sex, higher pre-stroke disability, less severe form of stroke (Lacunar 
Infarction) and no prior antiplatelet use before the index stroke. Clopidogrel use was associated 
with increased prevalence of a number of comorbid conditions including; Coronary Heart 
Disease/Myocardial Infarction, Hypertension, Hyperlipidemia, Diabetes Mellitus, Peripheral 
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Vascular Disease, Chronic Obstructive Pulmonary Disease and Chronic Kidney Disease. 
Aspirin/dipyridamole dual antiplatelet therapy was also associated with increased prevalence of a 
number of comorbidities, albeit to a lesser extent than clopidogrel monotherapy. These included 
Previous Stroke/Transient Ischaemic Attack, Coronary Heart Disease/Myocardial Infarction, 
Hypertension and Hyperlipidemia. Unadjusted Kaplan-Meier survival curves for patients receiving 
different antiplatelet therapies are depicted in Figure 1. Visual inspection of the curves suggested 
that both clopidogrel and aspirin plus dipyridamole are associated with better outcomes at ~2 
months compared to aspirin alone, after which the effectiveness of clopidogrel surpasses that of 
aspirin plus dipyridamole.  
Table 2 shows the risk of mortality and mortality + MACE according to antiplatelet therapy 
at various time intervals (0 – 90 days, 91 – 365 days, 1 – 3 years). After adjusting for potential 
confounders, we found that aspirin plus dipyridamole dual antiplatelet therapy was associated with 
a lower risk of mortality and mortality + MACE at 0 – 90 days compared to aspirin. Clopidogrel 
was associated with reduced risk of mortality and mortality + MACE at 1 – 3 years. Table 3 depicts 
adjusted hazard ratios of mortality and mortality + MACE for clopidogrel compared to aspirin plus 
dipyridamole. Clopidogrel had significantly better outcomes in the long term (1 – 3 years) and 
aspirin plus dipyridamole had significantly better outcomes in the short term (0 – 90 days). 
Supplementary Table 1 depicts crude rates of mortality, myocardial infarction and stroke according 
to discharge antiplatelet therapy. Aspirin had the highest rates of all three events whereas 
clopidogrel had the lowest.  
 
Discussion 
The current study found aspirin plus dipyridamole to be associated with better short term 
outcomes then aspirin monotherapy, with a 38% relative risk reduction in mortality 0 – 90 days 
after discharge. In contrast, clopidogrel use was associated with better longer term outcomes when 
compared to aspirin; with a 61% relative risk reduction in mortality at 1- 3 years after discharge. 
When comparing clopidogrel to aspirin plus dipyridamole directly, clopidogrel was significantly 
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associated with better mortality outcomes in the long term (1 – 3 years), whereas aspiring plus 
dipyridamole was significantly better in the short term (0 – 90 days).  
The CAPRIE trial evaluated the effectiveness of clopidogrel compared to aspirin [2] as 
preventative therapy in patients at risk of ischemic events. This trial demonstrated that patients with 
clopidogrel had a relative risk (RR) reduction of 7.3%, however, this was not statistically significant 
(p=0.26). Due to an observational design, the current study cannot be directly compared to the 
CAPRIE trial. The difference between our findings and those in the CAPRIE trial may be explained 
by the difference in means follow-up times; CAPRIE trial = 1.91 years and current study = 1.91 
years [8]. It is possible that by including all consecutively admitted strokes within the Norfolk 
region of the UK in combination with a long-term follow-up, our study captured the statistically 
significant improvements in outcome for clopidogrel, which occurred after 1-year post discharge. 
The observed long-term benefit of clopidogrel within the current study may be due to the reduced 
occurrence of recurrent stroke when compared to aspirin and aspirin plus dipyridamole (see crude 
rates of MACE in Supplementary Table 1). Furthermore, a meta-analysis has found clopidogrel to 
be associated with fewer bleeding complications when compared to aspirin as preventative therapy 
in cardiovascular disease [9]. While the appropriate data was not available in the current study, it is 
possible that clopidogrel led to better outcomes when compared to aspirin due to a reduced rate of 
bleeding complications. 
Six randomised controlled trials have compared the effectiveness of aspirin plus 
dipyridamole to aspirin monotherapy in improving outcomes in non-cardioembolic ischemic stroke 
[10 – 15]. A meta-analysis found aspirin plus extended release dipyridamole to be associated with a 
significant reduction in the RR of the composite endpoint of nonfatal stroke, nonfatal MI and 
vascular death; 0.82 (0.73 – 0.92) [16]. Patients in the current study who received aspirin and 
dipyridamole were given extended release dipyridamole. Interestingly, the current study observed 
favourable outcomes for aspirin and dipyridamole compared to aspirin monotherapy and 
clopidogrel in the short-term only. As an observational study we were unable to take into account 
the potential confounding effect of adherence associated with dipyridamole use. In the ESPS2 trial 
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(investigating the efficacy of aspirin/dipyridamole as secondary preventative therapy for ischemic 
stroke) 8% of patients on aspirin/dipyridamole had to withdraw due to headache [17]. For this 
reason, it is possible that poor adherence secondary to side effects accounts for the absence of any 
observed long-term benefit of aspirin plus dipyridamole over aspirin monotherapy in the current 
study.  
Newer antiplatelets such as ticagrelor are now used in patients with acute coronary 
syndromes [18], however, a recent trial has found that ticagrelor is non-superior to aspirin 
monotherapy for secondary prevention in non-cardioembolic stroke [19]. Similarly, dual-
antiplatelet therapy is routinely used in acute coronary syndromes, however, guidelines have 
recommended against the use of aspirin + clopidogrel for secondary prevention in stroke due to 
increased bleeding risk [4-6]. A recent meta-analysis of randomised trials analyzed the short term 
efficacy (≤ 1 year) of dual antiplatelet therapy (aspirin + clopidogrel and aspirin + dipyridamole) 
compared to monotherapy, for secondary prevention in non-cardioembolic ischemic stroke [20], 
found that both types of dual therapy were significantly associated with improved short term 
outcomes when compared to monotherapy, without a concomitant increase in adverse outcomes. 
These findings suggest that increased rates of bleeding events are more likely when dual antiplatelet 
therapy is used in the long term only. Patients with non-cardioembolic ischemic stroke may 
therefore benefit from initially receiving dual therapy such as aspirin plus dipyridamole, with a 
switch to monotherapy within 12 months, in a manner similar to patients with acute coronary 
syndromes [21].   
 This study had a number of limitations. Firstly, clinical factors may have informed the 
decision to prescribe a particular antiplatelet regimen to patients within the study. Furthermore, 
patients prescribed aspirin were concentrated in the years before 2011, whereas those prescribed 
clopidogrel were concentrated in the years after 2011 (Supplementary Figure 2). We have attempted 
to account for these potential sources of bias by adjusting for year of treatment in our multivariate 
analysis. We were also able to control for age, sex, pre-stroke disability, stroke severity and 
prognosis through OCSP classification, prior antiplatelet use and wide range of chronic co-
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morbidities which are important for both short and long term outcomes. Studies have shown pre-
morbid Rankin score [22] and OCSP classification [23] to be major determinants of mortality in 
stroke patients beyond short term mortality. However, as an observational study, we were unable to 
definitively account for confounding by indication and residual confounding. While we have 
attempted to exclude patients with cardioembolic stroke by excluding patients with AF, there is the 
possibility of some misclassification. While the current study was conducted on a population from a 
single center, thereby limiting the generalizability of our findings, the NNUH register captured all 
admissions for stroke within the Norfolk region of the United Kingdom and participants were 
identified prospectively with near complete follow-up was through data linkage to Office of 
National Statistics in the UK, to ascertain events. This method has been shown to have high validity 
[24]. In addition, we did not have data on compliance with medication, or control for changes in 
medication made in primary care after hospital discharge. Data specifying the cause of mortality 
were not available, meaning that we were unable to determine whether mortality was related to 
vascular pathology or other co-morbidities. Finally, data on bleeding outcomes was not available, 
which entailed that we were unable to assess this outcome.  
In summary, this study has demonstrated an association between aspirin plus dipyridamole 
dual therapy with better short-term outcomes and clopidogrel with better long-term outcomes when 
compared to aspirin monotherapy. Our findings therefore suggest that ischemic stroke patients may 
benefit from dual aspirin plus dipyridamole therapy initially (≤1 year) with a subsequent switch to 
clopidogrel therapy. Future studies evaluating the long-term impact of aspirin plus dipyridamole 
and clopidogrel should focus on additional outcomes such as bleeding risk and vascular death.  
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Figure Legend: 
 
 
Figure 1: Kaplan-Meier Survival Curve of Mortality Outcome by Antiplatelet Therapy 
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Table 1: Sample Characteristics by Discharge Antiplatelet Therapy   
Variable Aspirin Aspirin and 
Dipyridamole 
P-
Value 
Clopidogrel 
a  
 
P-
Value 
Total 
 (n = 
953) 
(n = 1,067)   
 
 
 
<0.001 
(n = 1,555)   
 
 
 
0.001 
(n = 
3,575) 
Age     
≤ 60 161 
(16.9 
%) 
98 (9.2 %) 223 (14.3 
%) 
482 
(13.5 
%) 
61 - 65 54 (5.7 
%) 
96 (9.0 %) 145 (9.3 %) 295 
(8.3 
%) 
66 - 70 81 (8.5 
%) 
104 (9.7 %) 171 (11.0 
%) 
356 
(10.0 
%) 
71 - 75 123 
(12.9 
%) 
147 (13.8 %) 212 (13.6 
%) 
482 
(13.5 
%) 
76 – 80 134 
(14.1 
%) 
205 (19.2 %) 241 (15.5 
%) 
580 
(16.2 
%) 
81 – 85 166 
(17.4 
%) 
214 (20.1 %) 259 (16.7 
%) 
639 
(17.9 
%) 
86 – 90 145 
(15.2 
%) 
143 (13.4 %) 194 (12.5 
%) 
482 
(13.5 
%) 
≥ 91  89 (9.3 
%) 
60 (5.6 %) 110 (7.1 %) 259 
(7.2 
%) 
Men 453 
(47.5 
%) 
564 (52.9 %)  
0.017 
797 (51.3 
%) 
 
0.071 
1,814 
(50.7 
%) 
Women 500 
(52.5 
%) 
503 (47.1 %) 758 (48.7 
%) 
1,761 
(49.3 
%) 
Pre-stroke mRS    
 
 
0.003 
  
 
 
<0.001 
 
0 648 
(68.0 
%) 
750 (70.3 %) 1070 (68.8 
%) 
2,468 
(69.0 
%) 
1 79 (8.3 
%) 
106 (9.9 %) 228 (14.7 
%) 
413 
(11.6 
%) 
2 67 (7.0 
%) 
89 (8.3 %) 102 (6.6 %) 258 
(7.2 
%) 
3 91 (9.5 
%) 
85 (8.0 %) 101 (6.5 %) 277 
(7.7 
%) 
4 56 (5.9 
%) 
29 (2.7 %) 40 (2.6 %) 125 
(3.5 
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%) 
5 12 (1.3 
%) 
8 (0.7 %) 14 (0.9 %) 34 
(1.0 
%) 
OCSP Classification    
 
0.081 
  
 
<0.001 
 
LACI 337 
(35.4 
%) 
383 (35.9 %) 458 (29.5 
%) 
1,178 
(33.0 
%) 
PACI 326 
(34.2 
%) 
389 (36.5 %) 619 (39.8 
%) 
1,334 
(37.3 
%) 
POCI 155 
(16.3 
%) 
185 (17.3 %) 276 (17.7 
%) 
616 
(17.2 
%) 
TACI 94 (9.9 
%) 
83 (7.8 %) 189 (12.2 
%)  
366 
(10.2 
%) 
Unspecified 41 (4.3 
%) 
27 (2.5 %) 13 (0.8 %) 81 
(2.3 
%) 
Prior Antiplatelet Use 230 
(24.1 
%) 
535 (50.1 %) <0.001 566 (36.4 
%) 
<0.001 1,331 
(37.2 
%) 
Co-Morbidities       
Previous 
Stroke/Transient 
Ischemic Attack 
165 
(17.3 
%) 
291 (27.3 %) <0.001 309 (19.9 
%) 
0.112 765 
(21.4 
%) 
Coronary Heart 
Disease / 
Myocardial 
Infarction 
71 (7.5 
%) 
133 (12.5 %) <0.001 222 (14.3 
%) 
<0.001 426 
(11.9 
%) 
Congestive 
Heart Failure 
23 (2.4 
%) 
35 (3.3 %) 0.244 58 (3.7 %) 0.070 116 
(3.2 
%) 
Hypertension 150 
(15.7 
%) 
234 (21.9 %) <0.001 480 (30.9 
%) 
<0.001 864 
(24.2 
%) 
Hyperlipidemia 9 (0.9 
%) 
39 (3.7 %) <0.001 92 (5.9 %) <0.001 140 
(3.9 
%) 
Diabetes 
Mellitus 
49 (5.1 
%) 
74 (6.9 %) 0.092 167 (10.7 
%) 
<0.001 290 
(8.1 
%) 
Peripheral 
Vascular 
Disease 
9 (0.9 
%) 
15 (1.4 %) 0.339 31 (2.0 %) 0.042 55 
(1.5 
%) 
Chronic 
Obstructive 
Pulmonary 
Disease 
23 (2.4 
%) 
25 (2.3 %) 0.917 61 (3.9 %) 0.041 109 
(3.0 
%) 
Chronic Kidney 
Disease 
11 (1.2 
%) 
12 (1.1 %) 0.950 51 (3.3 %) 0.001 74 
(2.1 
%) 
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Falls 101 
(10.6 
%) 
100 (9.4 %) 0.358 183 (11.8 
%) 
0.369 384 
(10.7 
%) 
Malignancy 91 (9.5 
%) 
86 (8.1 %) 0.237 157 (10.1 
%) 
0.656 334 
(9.3 
%) 
Dementia 13 (1.4 
%) 
11 (1.0 %) 0.490 37 (2.4 %) 0.077 61 
(1.7 
%) 
a 
Clopidogrel has been compared to Aspirin 
b 
OCSP = Oxford Community Stroke Project Classification, LACI = Lacunar Infarct, PACI = 
Partial Anterior Circulation Infarct, POCI = Posterior Circulation Infarct, TACI = Total Anterior 
Circulation Infarct. 
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Table 2: Hazard Ratios of Mortality and Mortality + incident MACE (major adverse cardiovascular 
event) at Different Time-periods for Clopidogrel and Aspirin + Dipyridamole compared to Aspirin 
(Cox Proportional Hazards Model) 
 
 
 Mortality Mortality + MACE 
a 
0 – 90 Days 
Aspirin 
Aspirin + Dipyridamole 
Clopidogrel 
 
1.00 
0.62 (0.43 – 0.91) 
0.97 (0.59 – 1.59) 
 
1.00 
0.70 (0.52 – 0.94) 
0.90 (0.60 – 1.36) 
91 – 365 Days 
Aspirin 
Aspirin + Dipyridamole 
Clopidogrel 
 
1.00 
0.80 (0.60 – 1.08) 
0.82 (0.54 – 1.25) 
 
1.00 
0.79 (0.59 – 1.06) 
0.84 (0.55 – 1.28) 
366 – 1095 Days 
Aspirin 
Aspirin + Dipyridamole 
Clopidogrel 
 
1.00 
0.98 (0.76 – 1.27) 
0.39 (0.26 – 0.60) 
 
1.00 
0.95 (0.73 – 1.24) 
0.57 (0.38 – 0.85) 
a 
MACE = incident stroke and/or myocardial infarction  
b 
All Cox-regression Models Adjusted For: Year Admitted, Age, Sex, Oxfordshire Community 
Stroke Project Classification, Pre-stroke modified Rankin score, Prior Antiplatelet Use, Co-
Morbidities (Previous Stroke/Transient Ischemic Attack, Myocardial Infarction/Coronary Heart 
Disease, Congestive Heart Failure, Hypertension, Hyperlipidemia, Diabetes Mellitus, Peripheral 
Vascular Disease, Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease, Falls, 
Malignancy, Dementia)  
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Table 3: Hazard Ratios of Mortality and Mortality + incident MACE (major adverse cardiovascular 
event) at Different Time-periods for Clopidogrel compared to Aspirin + Dipyridamole (Cox 
Proportional Hazards Model) 
 Mortality Mortality + MACE 
a
 
0 – 90 Days 
Aspirin + Dipyridamole 
Clopidogrel 
 
1.00 
1.77 (1.01 – 3.12) 
 
1.00 
1.49 (0.94 – 2.34) 
91 – 365 Days 
Aspirin + Dipyridamole 
Clopidogrel 
 
1.00 
1.19 (0.77 – 1.85) 
 
1.00 
1.29 (0.84 – 1.99) 
366 – 1095 Days 
Aspirin + Dipyridamole 
Clopidogrel 
 
1.00 
0.52 (0.33 – 0.81) 
 
1.00 
0.75 (0.49 – 1.15) 
a 
MACE = incident stroke and/or myocardial infarction  
b 
All Cox-regression Models Adjusted For: Year Admitted, Age, Sex, Oxfordshire Community 
Stroke Project Classification, Pre-stroke modified Rankin score, Prior Antiplatelet Use, Co-
Morbidities (Previous Stroke/Transient Ischemic Attack, Myocardial Infarction/Coronary Heart 
Disease, Congestive Heart Failure, Hypertension, Hyperlipidemia, Diabetes Mellitus, Peripheral 
Vascular Disease, Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease, Falls, 
Malignancy, Dementia)   
 
 
 
 
